{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:47:30Z","timestamp":1778633250031,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T00:00:00Z","timestamp":1470355200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The funding was supported through the Health Intervention and Technology Assessment Program from the National Health Security Office, Thailand"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12876-016-0506-4","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T01:58:46Z","timestamp":1470362326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6"],"prefix":"10.1186","volume":"16","author":[{"given":"Nattiya","family":"Kapol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surasit","family":"Lochid-amnuay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yot","family":"Teerawattananon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,5]]},"reference":[{"key":"506_CR1","unstructured":"World Health Organization. Hepatitis. 2014. http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA67\/A67_R6-en.pdf . Accessed 15 Oct 2014."},{"key":"506_CR2","unstructured":"Centers for Disease Control and Prevention. Hepatitis C: General information. 2010. http:\/\/www.cdc.gov\/hepatitis\/hcv\/pdfs\/hepcgeneralfactsheet.pdf . Accessed 20 Apr 2014."},{"key":"506_CR3","unstructured":"World Health Organization. Hepatitis C. 2013. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/ . Accessed 12 Apr 2013."},{"issue":"4","key":"506_CR4","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333\u201342.","journal-title":"Hepatology"},{"key":"506_CR5","doi-asserted-by":"crossref","unstructured":"Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, AlOmair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver International. 2011;31(s2):61\u201380.","DOI":"10.1111\/j.1478-3231.2011.02540.x"},{"issue":"3","key":"506_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1365-2893.2011.01563.x","volume":"19","author":"AC Khoury El","year":"2012","unstructured":"El Khoury AC, Klimack WK, Wallace C, Razavi H. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat. 2012;19(3):153\u201360.","journal-title":"J Viral Hepat"},{"issue":"5","key":"506_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3111\/13696998.2012.681332","volume":"15","author":"AC Khoury El","year":"2012","unstructured":"El Khoury AC, Wallace C, Klimack WK, Razavi H. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ. 2012;15(5):87\u201396.","journal-title":"J Med Econ"},{"issue":"2","key":"506_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s12072-012-9342-y","volume":"6","author":"M Omata","year":"2012","unstructured":"Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. 2012;6(2):409\u201335.","journal-title":"Hepatol Int"},{"issue":"9","key":"506_CR9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.4254\/wjh.v5.i9.496","volume":"5","author":"C Bunchorntavakul","year":"2013","unstructured":"Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T. Hepatitis C genotype 6: A concise review and response-guided therapy proposal. World J Hepatol. 2013;5(9):496\u2013504.","journal-title":"World J Hepatol"},{"issue":"4","key":"506_CR10","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"MG Ghany","year":"2009","unstructured":"Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335\u201374.","journal-title":"Hepatology"},{"issue":"2","key":"506_CR11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","volume":"60","author":"Eurapean Association for the Study of the Liver","year":"2014","unstructured":"Eurapean Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392\u2013420.","journal-title":"J Hepatol"},{"key":"506_CR12","first-page":"52","volume-title":"Thailand practice guideline for management of chronic hepatitis B and C 2012","author":"Thai Association for the Study of the Liver","year":"2012","unstructured":"Thai Association for the Study of the Liver. Thailand practice guideline for management of chronic hepatitis B and C 2012. 2nd ed. Bangkok: Thai Association for the Study of the Liver; 2012. p. 52.","edition":"2"},{"key":"506_CR13","first-page":"147","volume-title":"Research for development of health benefit package under universal health care coverage scheme: Issue 1","author":"P Werayingyong","year":"2011","unstructured":"Werayingyong P, Teerawattananon Y. Cost-utility and budget impact of the chronic hepatitis C treatment. In: International Health Policy Program (IHPP) and Health Intervention and Technology Assessment Program (HITAP), editor. Research for development of health benefit package under universal health care coverage scheme: Issue 1. Nontaburi: The Graphico System Co.Ltd; 2011. p. 147\u201372."},{"issue":"10","key":"506_CR14","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2893.2009.01226.x","volume":"17","author":"NH Nguyen","year":"2010","unstructured":"Nguyen NH, VuTien P, Garcia RT, Trinh H, Nguyen H, Nguyen K, et al. Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2\/3 vs 6. J Viral Hepat. 2010;17(10):691\u20137.","journal-title":"J Viral Hepat"},{"issue":"3","key":"506_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1136\/gut.52.3.425","volume":"52","author":"U Siebert","year":"2003","unstructured":"Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 2003;52(3):425\u201332.","journal-title":"Gut"},{"issue":"8","key":"506_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1365-2893.2006.00831.x","volume":"14","author":"S Gerkens","year":"2007","unstructured":"Gerkens S, Nechelput M, Annemans L, Peraux B, Mouchart M, Beguin C, et al. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C. J Viral Hepat. 2007;14(8):523\u201336.","journal-title":"J Viral Hepat"},{"issue":"101","key":"506_CR17","first-page":"939","volume":"57","author":"L Gheorghe","year":"2010","unstructured":"Gheorghe L, Baculea S. Cost-effectiveness of peginterferon alpha-2a and peginterferon alpha-2b combination regimens in genotype-1 naive patients with chronic hepatitis C. Hepatogastroenterology. 2010;57(101):939\u201344.","journal-title":"Hepatogastroenterology"},{"issue":"8","key":"506_CR18","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/j.1572-0241.2004.30286.x","volume":"99","author":"SD Sullivan","year":"2004","unstructured":"Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol. 2004;99(8):1490\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"506_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1590\/S1413-86702009000300007","volume":"13","author":"MC Fonseca","year":"2009","unstructured":"Fonseca MC, Araujo GT, Araujo DV. Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil. Braz J Infect Dis. 2009;13(3):191\u20139.","journal-title":"Braz J Infect Dis"},{"issue":"25","key":"506_CR20","first-page":"1","volume":"11","author":"FMR Barros","year":"2013","unstructured":"Barros FMR, Cheinquer H, Tsuchiya CT, Santos EAV. Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil. Cost Eff Resour Alloc. 2013;11(25):1\u20139.","journal-title":"Cost Eff Resour Alloc"},{"issue":"Suppl 2","key":"506_CR21","first-page":"S53","volume":"91","author":"U Permsuwan","year":"2008","unstructured":"Permsuwan U, Guntawongwan K, Buddhawongsa P. Handling time in economic evaluation studies. J Med Assoc Thai. 2008;91 Suppl 2:S53\u201358.","journal-title":"J Med Assoc Thai"},{"issue":"3","key":"506_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40265-013-0027-1","volume":"73","author":"N Flori","year":"2013","unstructured":"Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, et al. Pegylated interferon-alpha2a and ribavirin versus pegylated interferon-alpha2b and ribavirin in chronic hepatitis C: a meta-analysis. Drugs. 2013;73(3):263\u201377.","journal-title":"Drugs"},{"key":"506_CR23","unstructured":"Bureau of Policy and Strategy, Ministry of Public Health. Public health statistics 2011. Bangkok: The War Veterans Organization of Thailand Printing House. 2012. p. 58\u201361."},{"issue":"1","key":"506_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/0272989X03261568","volume":"24","author":"M Krahn","year":"2004","unstructured":"Krahn M, Wong JB, Heathcote J, Scully L, Seeff L. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Making. 2004;24(1):20\u20139.","journal-title":"Med Decis Making"},{"issue":"1","key":"506_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jhep.2010.01.033","volume":"53","author":"LH Omland","year":"2010","unstructured":"Omland LH, Krarup H, Jepsen P, Georgsen J, Harritshoj LH, Riison K, et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol. 2010;53(1):36\u201342.","journal-title":"J Hepatol"},{"issue":"2","key":"506_CR26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","volume":"112","author":"G Fattovich","year":"1997","unstructured":"Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463\u201372.","journal-title":"Gastroenterology"},{"issue":"5","key":"506_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jhep.2004.01.005","volume":"40","author":"R Planas","year":"2004","unstructured":"Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol. 2004;40(5):823\u201330.","journal-title":"J Hepatol"},{"issue":"3","key":"506_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3748\/wjg.v6.i3.339","volume":"6","author":"P Sithinamsuwan","year":"2000","unstructured":"Sithinamsuwan P, Piratvisuth T, Tanomkiat W, Apakupakul N, Tongyoo S. Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital. World J Gastroenterol. 2000;6(3):339\u201343.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"506_CR29","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0808010","volume":"361","author":"JG McHutchison","year":"2009","unstructured":"McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580\u201393.","journal-title":"N Engl J Med"},{"issue":"1","key":"506_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1053\/j.gastro.2009.08.071","volume":"138","author":"MG Rumi","year":"2010","unstructured":"Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010;138(1):108\u201315.","journal-title":"Gastroenterology"},{"issue":"9","key":"506_CR31","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00535-012-0560-9","volume":"47","author":"S Miyase","year":"2012","unstructured":"Miyase S, Haraoka K, Ouchida Y, Morishita Y, Fujiyama S. Randomized trial of peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin for chronic hepatitis C in Japanese patients. J Gastroenterol. 2012;47(9):1014\u201321.","journal-title":"J Gastroenterol"},{"issue":"6","key":"506_CR32","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1365-2893.2011.01566.x","volume":"19","author":"P Tangkijvanich","year":"2012","unstructured":"Tangkijvanich P, Komolmit P, Mahachai V, Poovorawan K, Akkarathamrongsin S, Poovorawan Y. Response-guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study. J Viral Hepat. 2012;19(6):423\u201330.","journal-title":"J Viral Hepat"},{"key":"506_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.vhri.2013.09.002","volume":"3","author":"S Thongsawat","year":"2014","unstructured":"Thongsawat S, Piratvisuth T, Pramoolsinsap C, Chutaputti A, Tanwandee T, Thongsuk D. Resource Utilization and Direct Medical Costs of Chronic Hepatitis C in Thailand: A Heavy but Manageable Economic Burden. Value Health Reg Issues. 2014;3:12\u20138.","journal-title":"Value Health Reg Issues"},{"key":"506_CR34","unstructured":"Riewpaiboon A. Standard Cost List for Health Technology Assessment. 2010. http:\/\/costingmenu.hitap.net\/ . Accessed 10 Nov 2013."},{"key":"506_CR35","unstructured":"Ministry of Public Health. Drug and medical supply information center. 2013. http:\/\/dmsic.moph.go.th\/dmsic\/index.php?p=1&id=1 . Accessed 10 Nov 2013."},{"issue":"1","key":"506_CR36","first-page":"2","volume":"5","author":"T Piratvisuth","year":"2004","unstructured":"Piratvisuth T, Tanwandee T, Mahachai V, Chutaputti A, Thongsawat S, Khow-Ean U, et al. The efficacy of peginterferon alfa-2b plus ribavirin combination in Thai patients with chronic hepatitis c. Thai J Gastroenterol. 2004;5(1):2\u20137.","journal-title":"Thai J Gastroenterol"},{"issue":"5","key":"506_CR37","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s11096-015-0144-x","volume":"37","author":"HJ Yang","year":"2015","unstructured":"Yang HJ, Ryoo JY, Yoo BK. Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection. Int J Clin Pharm. 2015;37(5):698\u2013708.","journal-title":"Int J Clin Pharm"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-016-0506-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-016-0506-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-016-0506-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-016-0506-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T20:00:11Z","timestamp":1498334411000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-016-0506-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,5]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["506"],"URL":"https:\/\/doi.org\/10.1186\/s12876-016-0506-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,5]]},"article-number":"91"}}